Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Andrew J. Plodkowski, MD"'
Autor:
Noura J. Choudhury, MD, Jaime L. Schneider, MD, PhD, Tejas Patil, MD, Viola W. Zhu, MD, PhD, Debra A. Goldman, MS, Soo-Ryum Yang, MD, Christina J. Falcon, MPH, Andrew Do, BS, Yunan Nie, MD, Andrew J. Plodkowski, MD, Jamie E. Chaft, MD, Subba R. Digumarthy, MD, Natasha Rekhtman, MD, PhD, Maria E. Arcila, MD, Alexia Iasonos, PhD, Sai-Hong I. Ou, MD, PhD, Jessica J. Lin, MD, Alexander Drilon, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187- (2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha
Externí odkaz:
https://doaj.org/article/81bc0a6f5dc849f182e47505ceaaaec1
Autor:
Donata von Reibnitz, BS, Jamie E. Chaft, MD, Abraham J. Wu, MD, Robert Samstein, MD, PhD, Matthew D. Hellmann, MD, Andrew J. Plodkowski, MD, Zhigang Zhang, PhD, Weiji Shi, MS, Rosalind Dick-Godfrey, BS, Kelly H. Panchoo, BA, Christopher A. Barker, MD, Andreas Rimner, MD
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 3, Pp 391-398 (2018)
Purpose: The objective of this study was to evaluate adverse events (AEs) in patients who received both immune checkpoint inhibitors and thoracic radiation therapy (RT). In particular, we compared the rate of toxicities of concurrent versus sequentia
Externí odkaz:
https://doaj.org/article/fc91151be2b946a0b97011bf86638875